Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease.

@article{Beglinger2009RandomizedCT,
  title={Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease.},
  author={Leigh J. Beglinger and Williams H Adams and Henry L. Paulson and Jess G Fiedorowicz and Douglas R. Langbehn and Kevin M. Duff and Anne L. Leserman and Jane S. Paulsen},
  journal={Journal of clinical psychopharmacology},
  year={2009},
  volume={29 5},
  pages={484-7}
}
BACKGROUND Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder. METHODS Twenty participants with mild Huntington disease who complained of inattention were randomized to receive atomoxetine (80 mg/d) or placebo in a 10-week… CONTINUE READING
12 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Neuropsychology of adults with Beglinger et al

  • AS Hervey, JN Epstein, JF. Curry
  • Journal of Clinical Psychopharmacology & Volume…
  • 2009

Similar Papers

Loading similar papers…